COX‐2 inhibitors arrest prostate cancer cell cycle progression by down‐regulation of kinetochore/centromere proteins

J Bieniek, C Childress, MD Swatski, W Yang - The Prostate, 2014 - Wiley Online Library
BACKGROUND Previous studies have shown that COX‐2 inhibitors inhibit cancer cell
proliferation. However, the molecular mechanism remains elusive. METHODS Prostate …

Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity

N Hayashi, E Koller, L Fazli, ME Gleave - The Prostate, 2008 - Wiley Online Library
OBJECTIVES Microtubular inhibitors, including docetaxel, are active cytotoxics in many
cancers, including prostate cancer (CaP). The Eg5 gene, a member of the kinesin‐5 family …

EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer

E Kashiwagi, M Shiota, A Yokomizo… - Prostate cancer and …, 2014 - nature.com
Background: Non-steroidal anti-inflammatory drugs inhibit the activity of cyclooxygenases
(COXs), and their usage reduces the risks associated with prostate cancer. Celecoxib is a …

Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models

X Li, Y Chen, L Bai, R Zhao, Y Wu, ZR Xie… - British Journal of …, 2023 - nature.com
Background It is imperative to develop novel therapeutics to overcome chemoresistance, a
significant obstacle in the clinical management of prostate cancer (PCa) and other cancers …

CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway Corrigendum in/10.3892/or. 2023.8602

J Ji, T Shen, Y Li, Y Liu, Z Shang… - Oncology …, 2021 - spandidos-publications.com
Cell division cycle-associated 5 (CDCA5) can regulate cell cycle-related proteins to promote
the proliferation of cancer cells. The purpose of the present study was to investigate the …

Suppression of N-Methyl-N-nitrosourea/Testosterone-induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and …

BA Narayanan, MS Condon, MC Bosland… - Clinical Cancer …, 2003 - AACR
Purpose: This study was aimed at examining the mechanisms underlying the
chemopreventive effect of celecoxib against prostate cancer. We focused our attention on …

Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression

F Zhu, P Liu, J Li, Y Zhang - Oncology reports, 2014 - spandidos-publications.com
Chemokines have been reported to play crucial roles in tumor progression. Eotaxin-1
(CCL11), a member of the CC chemokine family, is elevated in many types of human cancer …

[HTML][HTML] A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-ℒ-cysteine, a novel Eg5 inhibitor

ND Xing, ST Ding, R Saito, K Nishizawa… - Asian journal of …, 2011 - ncbi.nlm.nih.gov
Docetaxel-based combination chemotherapy remains the predominant treatment for
castration-resistant prostate cancer. However, taxane-related drug resistance and …

Cyclooxygenase‐2 promotes prostate cancer progression

H Fujita, K Koshida, ET Keller, Y Takahashi… - The …, 2002 - Wiley Online Library
Abstract BACKGROUND Cyclooxygenase (COX)‐2, an inducible isoform of COX, has been
observed to be expressed in prostate cancer. Several studies have reported that COX‐2 …

RNA interference–mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein …

BA Narayanan, NK Narayanan, L Davis… - Molecular cancer …, 2006 - AACR
Abstract Cyclooxygenase-2 (COX-2) plays an important role in tumor development and
progression. Inconsistent reports on the expression of COX-2 in early versus advanced …